Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNX-1810
- Development stage
- Preclinical
- Lead developer
- Tonix Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal
01
Overview
TNX-1810 is a preclinical live attenuated vaccine candidate being developed by Tonix Pharmaceuticals in collaboration with the University of Alberta for the prevention of COVID-19. It utilizes Tonix's proprietary horsepox virus vector platform to express SARS-CoV-2 antigens other than the Spike protein. Unlike many first-generation COVID-19 vaccines that focus on neutralizing antibodies against the Spike protein, TNX-1810 is specifically designed to elicit a robust T-cell-mediated immune response. This approach aims to provide broader and potentially more durable protection against viral variants by targeting more conserved internal viral proteins.
Beyond the preview
Go deeper on TNX-1810.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNX-1810.